Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 11;159(9):e61.
doi: 10.1016/j.medcli.2022.05.016. Epub 2022 Jul 20.

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic

[Article in English, Spanish]
Chia Siang Kow  1 , Dinesh Sangarran Ramachandram  2 , Syed Shahzad Hasan  3
Affiliations
Comment

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic

[Article in English, Spanish]
Chia Siang Kow et al. Med Clin (Barc). .
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Méndez Bailón M, Azaña Gómez J, Pérez Belmonte L. Méndez Bailón M, et al. Med Clin (Barc). 2022 Nov 11;159(9):e62. doi: 10.1016/j.medcli.2022.06.002. Epub 2022 Aug 16. Med Clin (Barc). 2022. PMID: 35985894 Free PMC article. English, Spanish. No abstract available.

Comment on

References

    1. Azaña Gómez J., Pérez-Belmonte L.M., Rubio-Rivas M., Bascuñana J., Quirós-López R., Taboada Martínez M.L., et al. Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: data from the SEMI-COVID-19 registry [published online ahead of print, 2022 Mar 10] Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19 [published online ahead of print, 2022 Mar 10]Med Clin (Barc) 2022 S0025-7753(22)00054-9. - PMC - PubMed
    1. Toubasi A.A. Effect on morbidity and mortality of direct oral anticoagulants in patients with COVID-19 [published online ahead of print, 2022 Mar 12] Am J Cardiol. 2022 S0002-9149(22)00130-8. - PMC - PubMed
    1. Kow C.S., Hasan S.S. Pharmacologic therapeutic options for thromboprophylaxis in COVID-19. J Thromb Thrombolysis. 2021;51:29–30. - PMC - PubMed
    1. Kirchhof P., Ezekowitz M.D., Purmah Y., Schiffer S., Meng I.L., Camm A.J., et al. Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial. TH Open. 2020;4:e20–e32. - PMC - PubMed
    1. Kow C.S., Sunter W., Bain A., Zaidi S.T.R., Hasan S.S. Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. Am J Cardiovasc Drugs. 2020;20:301–309. - PMC - PubMed